Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-score
Our recently published K1N2-score robustly predicts KEAP1/NFE2L2-mutations and pathway activation status, while its accessibility might be limited. We tested if the RNA expression data of six pathway-related genes and NQO1-IHC might be a reliable alternative using 348 KEAP1/NFE2L2 mutation-enriched NSCLC. While TXNRD1 RNA testing was the best-performing single-gene test, the combination of single-gene screening and validation with the K1N2-score achieved the highest performance when predicting mutation status or pathway activation.
Authors
- Luigi Catanzariti
- Reinhard Büttner (ORCID: https://orcid.org/0000-0001-8806-4786)
- Andreas Hans Scheel (ORCID: https://orcid.org/0000-0003-0244-1646)
- Margaret Dugan
- Svenja Wagener‐Ryczek (ORCID: https://orcid.org/0000-0002-2870-5606)
- Barbara Holz
- Christoph Arolt (ORCID: https://orcid.org/0000-0002-6366-2285)
- Axel M. Hillmer (ORCID: https://orcid.org/0000-0002-3381-7266)
- Matthias Scheffler (ORCID: https://orcid.org/0000-0002-9031-1368)
- Vanessa Richartz
- Sabine Merkelbach‐Bruse (ORCID: https://orcid.org/0000-0002-0312-5760)
- Johannes Brägelmann (ORCID: https://orcid.org/0000-0002-1306-2169)
- Juergen Wolf
- Robert Wild (ORCID: https://orcid.org/0000-0001-9182-3587)
Institutions
- TH Köln - University of Applied Sciences (DE)
- University of Cologne (DE)
- Integrated Oncology (United States) (US)
- Tracon Pharmaceuticals (United States) (US)
- University Hospital Cologne (DE)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1038/s41698-024-00744-1
- Citations
- 1
- Primary Topic
- Coenzyme Q10 studies and effects
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe